Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia

Launched by MOSCOW PSYCHIATRIC HOSPITAL NO. 1 NAMED AFTER N.A. ALEXEEV · Dec 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Transcranial Magnetic Stimulation (TMS) to see how effective and safe it is for people with catatonia, a condition that can occur in various mental health disorders like schizophrenia, bipolar disorder, and major depressive disorder. The goal is to understand if TMS can help reduce symptoms of catatonia, which may include unusual movements, difficulties with speech, or not responding to others.

To participate in this trial, individuals must have a confirmed diagnosis of one of the specified mental health disorders and be experiencing certain symptoms of catatonia. Participants can include both adults and elderly individuals, and they should be able to cooperate with the treatment process, possibly with the help of caregivers. During the trial, participants will receive TMS treatment and will be monitored for its effects on their symptoms. It's important to note that individuals who are at risk of harming themselves or who are experiencing certain severe symptoms will not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Verified diagnosis of schizophrenic or affective spectrum (schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder)
• • Patient's ability (possibly accompanied by caregivers) to undergo diagnostic and therapeutic procedures;
• The presence of residual catatonia in the form of such psychomotor anomalies as:
• • disorganisation of thinking with speech disturbance with verbigerations and/or sperrungs
• • hypo- and hyperkinetic psychomotor phenomena;
• • substupor without disturbance of consciousness;
• • elective mutism;
• • echo phenomena (echolalia and/or echopraxia);
• • phenomena of "wax flexibility"
• • speech and behavioral stereotypy
• • pathetic exaltation phenomena
• • the phenomenon of irritative asthenia
• • dysuric phenomena (monotonous activity and rigidity of affect)
• Exclusion Criteria:
• • patient's refusal to participate in the study
• • acute hallucinatory-delusional symptoms
• • suicide risk
• • a patient taking prohibited therapy products
• • neuroleptic complications of antipsychotic therapy
• • irritative asthenia
• • dysuric phenomena by the type of monotonous activity and rigidity of affect